Publications
Detailed Information
Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kyubo | - |
dc.contributor.author | Chie, Eui Kyu | - |
dc.contributor.author | Wu, Hong-Gyun | - |
dc.contributor.author | Ha, Sung W | - |
dc.contributor.author | Kim, Jae Sung | - |
dc.contributor.author | Kim, In Ah | - |
dc.contributor.author | Lee, Hyo-Pyo | - |
dc.date.accessioned | 2009-11-25T23:44:30Z | - |
dc.date.available | 2009-11-25T23:44:30Z | - |
dc.date.issued | 2005-11-07 | - |
dc.identifier.citation | Gynecol Oncol. 2006 Jun;101(3):398-402. Epub 2005 Dec 5. | en |
dc.identifier.issn | 0090-8258 (Print) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16330087 | - |
dc.identifier.uri | https://hdl.handle.net/10371/15514 | - |
dc.description.abstract | OBJECTIVE: To evaluate the efficacy and safety of concurrent chemoradiotherapy with paclitaxel and carboplatin after hysterectomy for early stage uterine cervical carcinoma with high risk factors. METHODS: Between March 2000 and July 2002, 37 patients with stages IB-IIB uterine cervical carcinoma were treated with radical hysterectomy and bilateral pelvic lymph node dissection followed by concurrent chemoradiotherapy (POCCRT) with two courses of paclitaxel (135 mg/m(2)) and carboplatin (area under the time-concentration curve 4.5 mg min/ml) at 4-week interval. All the patients received external beam radiotherapy up to 50.4 Gy to the whole pelvis. Among these, 7 patients with close or involved resection margin received boost irradiation to the vaginal cuff (4 patients with low dose rate brachytherapy and 3 patients with external beam). Median dose of boost irradiation was 14.4 Gy (range: 14.4-34.6). RESULTS: Toxicity to POCCRT was mainly hematological and gastrointestinal, mostly grades 1 and 2. At a median follow-up of 27 months (range; 10-46), all the patients achieved local control, and 4 patients experienced distant relapses. The failure sites were as follows: bone (2 patients), paraaortic lymph node (1 patient), and supraclavicular lymph node (1 patient). CONCLUSIONS: Concurrent chemoradiotherapy with paclitaxel and carboplatin after hysterectomy is well tolerated and produces excellent local control rate despite of short follow-up period. This regimen could be considered for a phase III trial. | en |
dc.language.iso | en | - |
dc.publisher | Elsevier | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Antineoplastic Combined Chemotherapy Protocols/adverse | en |
dc.subject | effects/*therapeutic use | en |
dc.subject | Carboplatin/administration & dosage/adverse effects | en |
dc.subject | Combined Modality Therapy | en |
dc.subject | Disease-Free Survival | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Hysterectomy | en |
dc.subject | Lymph Node Excision | en |
dc.subject | Middle Aged | en |
dc.subject | Neoplasm Staging | en |
dc.subject | Paclitaxel/administration & dosage/adverse effects | en |
dc.subject | Patient Compliance | en |
dc.subject | Radiotherapy | en |
dc.subject | Risk Factors | en |
dc.subject | Uterine Cervical Neoplasms/drug therapy/pathology/radiotherapy/*therapy | en |
dc.title | Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 김규보 | - |
dc.contributor.AlternativeAuthor | 지의규 | - |
dc.contributor.AlternativeAuthor | 우홍균 | - |
dc.contributor.AlternativeAuthor | 김재성 | - |
dc.contributor.AlternativeAuthor | 김인아 | - |
dc.contributor.AlternativeAuthor | 이효표 | - |
dc.identifier.doi | 10.1016/j.ygyno.2005.10.035 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.